Jared Cumming, Merck, to Give a Presentation at GTCbios Protease Inhibitors Conference
Summary
Extensive genetic and pharmacological studies in animals and humans have shown that BACE1 inhibition has the potential to slow or halt the progression of AD with a sufficient therapeutic window for the requisite long term dosing.Dr. Cumming and his team at Merck have now designed an additional imino heterocycle scaffold and in parallel have worked to further optimize binding interactions in sub-sites adjacent to the catalytic dyad.Extensive genetic and pharmacological studies in animals and humans have shown that BACE1 inhibition has the potential to slow or halt the progression of AD with a sufficient therapeutic window for the requisite long term dosing.Dr. Cumming and his team at Merck have now designed an additional imino heterocycle scaffold and in parallel have worked to further optimize binding interactions in sub-sites adjacent to the catalytic dyad.Jared’s experience has run the gamut from fragment based drug design to lead optimization to working with clinical development teams.